Open AccessRandomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Author(s) -
Antonio C. Wolff,
Ann Lazar,
Igor Bondarenko,
August Garin,
Stephen Brincat,
Louis W.C. Chow,
Yan Sun,
Zora NeškovićKonstantinović,
Rodrigo C. Guimarães,
P. Fumoleau,
Arlene Chan,
Soulef Hachemi,
Andrew Strahs,
Maria Cincotta,
Anna Berkenblit,
Mizue Krygowski,
Lih Lisa Kang,
Laurence Moore,
Daniel F. Hayes
Publication year - 2012
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2011.38.3331
Subject(s) - temsirolimus , letrozole , medicine , everolimus , hazard ratio , metastatic breast cancer , oncology , clinical endpoint , breast cancer , progression free survival , exemestane , denosumab , aromatase inhibitor , placebo , randomized controlled trial , cancer , aromatase , confidence interval , chemotherapy , pathology , pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , biochemistry , osteoporosis , alternative medicine , chemistry , apoptosis
Recent data showed improvement in progression-free survival (PFS) when adding everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/progression after nonsteroidal aromatase inhibitor (AI) therapy. Here, we report clinical outcomes of combining the mammalian target of rapamycin (mTOR) inhibitor temsirolimus with letrozole in AI-naive patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom